Manufacturing validation of biologically functional T cells targeted to CD19 antigen for autologous adoptive cell therapy. - Test2 - elhamkhani - TriplyDB

Manufacturing validation of biologically functional T cells targeted to CD19 antigen for autologous adoptive cell therapy.

Manufacturing validation of biologically functional T cells targeted to CD19 antigen for autologous adoptive cell therapy.

http://www.wikidata.org/entity/Q37196769

about

CAR models: next-generation CAR modifications for enhanced T-cell function Clinical manufacturing of CAR T cells: foundation of a promising therapy Novel immunotherapies in lymphoid malignancies CAR T Cell Therapy: A Game Changer in Cancer Treatment Strategies and Advancements in Harnessing the Immune System for Gastric Cancer Immunotherapy T-cell and natural killer cell therapies for hematologic malignancies after hematopoietic stem cell transplantation: enhancing the graft-versus-leukemia effect Using gene therapy to manipulate the immune system in the fight against B-cell leukemias Current translational and clinical practices in hematopoietic cell and gene therapy A novel ex vivo isolation and expansion procedure for chimeric antigen receptor engrafted human T cells Toxicity and management in CAR T-cell therapy CD19-Chimeric Antigen Receptor T Cells for Treatment of Chronic Lymphocytic Leukaemia and Acute Lymphoblastic Leukaemia CAR therapy: the CD19 paradigm Manufacture of tumor- and virus-specific T lymphocytes for adoptive cell therapies Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias Engineered T cells for cancer treatment Biology and clinical application of CAR T cells for B cell malignancies Successful eradication of established peritoneal ovarian tumors in SCID-Beige mice following adoptive transfer of T cells genetically targeted to the MUC16 antigen.CAR-modified T-cell therapy for cancer: an updated review.Universal artificial antigen presenting cells to selectively propagate T cells expressing chimeric antigen receptor independent of specificity.Simplified process for the production of anti-CD19-CAR-engineered T cells Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor.Chimeric antigen receptors for T cell immunotherapy: current understanding and future directions Efficient clinical scale gene modification via zinc finger nuclease-targeted disruption of the HIV co-receptor CCR5 The promise and potential pitfalls of chimeric antigen receptors.Large-scale clinical-grade retroviral vector production in a fixed-bed bioreactor.Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity.NCI First International Workshop on The Biology, Prevention and Treatment of Relapse after Allogeneic Hematopoietic Cell Transplantation: report from the committee on prevention of relapse following allogeneic cell transplantation for hematologic ma Clinical scale rapid expansion of lymphocytes for adoptive cell transfer therapy in the WAVE® bioreactor.Immunotherapy of malignant disease using chimeric antigen receptor engrafted T cells The Promise of Chimeric Antigen Receptor Engineered T Cells in the Treatment of Hematologic Malignancies Cellular therapies in acute lymphoblastic leukemia Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition.Imaging of Sleeping Beauty-Modified CD19-Specific T Cells Expressing HSV1-Thymidine Kinase by Positron Emission Tomography.Treatment of lymphoma with adoptively transferred T cells.EGFRvIII mCAR-modified T-cell therapy cures mice with established intracerebral glioma and generates host immunity against tumor-antigen loss.Challenges of T cell therapies for virus-associated diseases after hematopoietic stem cell transplantation.Genetic redirection of T cells for cancer therapy.Progress and prospects: graft-versus-host disease.

P2860

Q26745600-E8C9C058-0F94-433F-B7C8-79D5DBC47364 Q26747037-B8F6C601-BB9C-4A51-885E-72F9ED336156 Q26777394-6B012261-FFA7-4C11-9609-4446DA920E66 Q26822769-1B7434FF-7F5C-4B7B-ADB3-643B0B001960 Q26823515-E0ACCBFC-6F89-4093-8AD1-D9AB1924DB71 Q26826830-4D9B81E3-427B-43C5-A125-F9D8DEE70E14 Q27011297-EBF4A35C-4C88-44BA-981A-AA97DBBDDC20 Q27024456-73DED1E9-7442-4D48-8D9B-F9B1F2671D3B Q27345360-1DC93E66-EAD5-423B-8AA2-5E974C71960C Q28075314-90644DBE-75F4-424C-9A39-1AF0243FF428 Q28081600-3372423E-3D8D-4687-9265-DB18FC7A1498 Q28081642-47B4D8CB-F98E-4A69-B199-DA73E917DAB1 Q28085769-8D26DFD5-2143-4A6A-84A8-63F4674646A7 Q29617590-05ACB8EE-5BD3-49C6-A7C7-688FC0DA38E4 Q29620607-46CC45FE-CCED-4127-8F14-FF21A9D8022F Q29622949-42E44D19-C628-4D5A-8F85-4AD5DF6C6D08 Q33578792-98985384-A786-4C2F-AE4C-34D4505023A6 Q33907565-01E38BBA-AEEE-4C3D-BAB3-62A7CC554FE3 Q34007762-139F1C91-0903-4444-AFDA-FA5A4C0B0403 Q34044213-11FBE1E0-7CFE-4B28-9F91-32AA42ADEE54 Q34069803-E1B5E20E-EB4C-4674-AC92-BCAEBEAD0A15 Q34078460-894B07A1-DB9A-42E1-BD88-FC5385F85801 Q34122292-0BF045A1-0826-4E3D-8170-EB99AAE8E5C5 Q34248531-C2222D1A-E983-4311-863B-062A2493146D Q34325074-EE390284-6A7B-4647-8CF9-07ECAA7AE5A2 Q34970378-6AC717D8-24CA-4BA9-B1C5-1ACBF5BAFB91 Q35158636-BE7A550A-0F04-43D0-A253-0C4669C2F2BA Q35216278-2EB4124E-DFD0-4E1C-94D3-CEB00003813B Q35605318-90006FB9-9D0F-4624-A14D-7F8F20007D99 Q36110862-737D2211-322A-484B-AFE8-3FA2414D6E8B Q36470354-9BC23A30-B305-41CC-BE40-418626DAE5E9 Q36547199-9C60EB2E-2158-4CF9-8799-9200FC3FDC2A Q36552098-EEF23A0F-A851-44DC-9EEB-424EFB1EBBE9 Q37137924-CAD2B854-9FF6-4759-B92D-C2BBC314F46F Q37395931-73A93567-5B3C-4B73-8CAD-6F4A0AB18E44 Q37419728-1FCBBDAD-D7C6-4A7E-AE1A-B130F76A7AB1 Q37618652-3CBA11C3-7F57-4E89-A31B-EEC87B196C4F Q37687412-CCA58A94-D2E1-420E-B4D2-9C21AB48C6B2 Q37697337-9A436F96-93E3-4D00-B0CC-EE18390F9E7F Q37761297-2C8A672A-EC67-49D4-9DF1-302DF68B0293

P2860

Manufacturing validation of biologically functional T cells targeted to CD19 antigen for autologous adoptive cell therapy.

http://www.wikidata.org/entity/Q37196769

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on February 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Manufacturing validation of bi ...... ologous adoptive cell therapy.

@en

Manufacturing validation of bi ...... ologous adoptive cell therapy.

@nl

type

label

Manufacturing validation of bi ...... ologous adoptive cell therapy.

@en

Manufacturing validation of bi ...... ologous adoptive cell therapy.

@nl

prefLabel

Manufacturing validation of bi ...... ologous adoptive cell therapy.

@en

Manufacturing validation of bi ...... ologous adoptive cell therapy.

@nl

P1433

Q37196769-3DFAA69C-9639-45EA-A178-8406A9CBE55F

P1476

Q37196769-A7167C27-0973-41DB-B5AF-9428A69F6CD0

P2093

Q37196769-01BD1192-078F-49A2-9A5E-5DAF8053239D

Q37196769-032CA8DF-5382-4728-9EAB-3A44D11106A1

Q37196769-2324D3E0-56DC-4FE5-8719-88C6AF6DE332

Q37196769-38F1FFED-8704-4107-BD5D-FFBBE52380FD

Q37196769-6F4EEA88-9BDC-4C48-9EB8-CAFC5E093D03

Q37196769-7424FBA4-B93E-4484-8A37-262C7D8DA70E

Q37196769-97416218-F407-4679-8358-8C0381423ECB

Q37196769-B0F77F80-C961-4232-B51A-E7CC28AD8EED

Q37196769-BA676F7D-33FF-402E-9751-35D5D2EFAD01

Q37196769-BC9E5213-71D5-46C2-8424-638151EF502C

P2860

Q37196769-01553A9F-BBC6-40A1-9B2D-65E551B85F17

Q37196769-03652F7E-4402-4AC5-9D86-E579B106A8A4

Q37196769-0A41E350-3EDD-4369-B14D-9950C401C65A

Q37196769-10D60D7F-758A-4CDE-8A8E-0DA431559159

Q37196769-181CE278-0BA8-4E31-927A-89E5484BD710

Q37196769-1C588A13-7819-4CAA-9B80-CC8153EA4C9B

Q37196769-314697BD-4AE3-496D-A901-6EF495B19A3C

Q37196769-377E8A5D-2402-4ECD-AF17-4FE5BB431A3D

Q37196769-4C72B999-871D-4735-A6A6-25FAF73FF959

Q37196769-57F9B49A-2429-44DC-BE15-C97D88D77ABC

P304

Q37196769-428C2927-2626-49A9-8394-A7171049C615

P31

Q37196769-B7096221-3B61-4C69-AF4B-F8E7D21B4727

P356

Q37196769-AE593E9F-EA58-4745-BB3B-0490C4D170D0

P433

Q37196769-DF15F151-6770-438F-87A6-40BF7ADDDB98

P478

Q37196769-A8B97324-18C4-4971-B654-4BFC171CC34C

P577

Q37196769-53016924-C0AD-4CD3-9B20-8B0E004A0020

P698

Q37196769-5F1D7D4A-E329-4755-A84D-A06FCB256BFE

P932

Q37196769-0939F9BF-A2EE-4B6A-82FA-402E269EA396

P356

CJI.0B013E318194A6E8

P1433

Journal of Immunotherapy

P1476

Manufacturing validation of bi ...... ologous adoptive cell therapy.

@en

P2093

Clare Taylor

http://www.w3.org/2001/XMLSchema#string

Daniel Hollyman

http://www.w3.org/2001/XMLSchema#string

Isabelle Rivière

http://www.w3.org/2001/XMLSchema#string

James Hosey

http://www.w3.org/2001/XMLSchema#string

Jolanta Stefanski

http://www.w3.org/2001/XMLSchema#string

Malgorzata Olszewska

http://www.w3.org/2001/XMLSchema#string

Mark Przybylowski

http://www.w3.org/2001/XMLSchema#string

Michel Sadelain

http://www.w3.org/2001/XMLSchema#string

Oriana Borquez-Ojeda

http://www.w3.org/2001/XMLSchema#string

Raymond Yeh

http://www.w3.org/2001/XMLSchema#string

P2860

Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma

Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1

Cancer regression in patients after transfer of genetically engineered lymphocytes

Optimization of human T-cell expansion ex vivo using magnetic beads conjugated with anti-CD3 and Anti-CD28 antibodies

Central memory and effector memory T cell subsets: function, generation, and maintenance

Effects of retroviral vector design on expression of human adenosine deaminase in murine bone marrow transplant recipients engrafted with genetically modified cells.

Interaction of Staphylococcus aureus toxin "superantigens" with human T cells

Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells

CD8+ T-cell memory in tumor immunology and immunotherapy.

Advances in the therapy of chronic lymphocytic leukemia.

P304

169-180

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/CJI.0B013E318194A6E8

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

32

http://www.w3.org/2001/XMLSchema#string

P577

2009-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19238016

http://www.w3.org/2001/XMLSchema#string

P932

2683970

http://www.w3.org/2001/XMLSchema#string